• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
SPL
Click for more information
0.00% 10.5¢

STARPHARMA HOLDINGS LIMITED - Announcements

Market Cap $43.82M  ! watchlist Created with Sketch. Add to my watchlist

Starpharma Holdings Limited is an Australia-based biopharmaceutical company. The... Starpharma Holdings Limited is an Australia-based biopharmaceutical company. The principal activities of the Company consist of research, development and commercialization of dendrimer products for pharmaceutical, life-science and other applications. It is focused on developing and commercializing novel therapeutic products that address global healthcare needs. The Company is also involved in the development of nano-scale materials, including the development of VivaGel for the management and prevention of bacterial vaginosis, and as an antiviral condom coating, and VIRALEZE, an antiviral nasal spray. The Company is also applying its proprietary dendrimers to drug delivery to create improved pharmaceuticals and has developed the valuable DEP delivery platform. VIRALEZE is a broad-spectrum nasal spray intended to provide a moisturizing and protective barrier in the nose that traps and blocks cold/respiratory viruses. It also offers VivaGel BV and VivaGel Condom products.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW
TRADE NOW
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW

Filter Results
All Price Sensitive Only
search Created with Sketch. Search
search Created with Sketch. Search
SPL Appendix 4C - Quarterly Cashflow ReportPRICE SENSITIVE30/04/15
SPL DEP Docetaxel Trial Dose Exceeds Common Taxotere Dose LevelPRICE SENSITIVE30/04/15
SPL Securities Dealing Policy22/04/15
SPL Shareholder Update March 201523/03/15
SPLShareholder Update March 201523/03/15
SPL Starpharma to present at March US investor conferences05/03/15
SPL Starpharma presents at ASX Investor Series17/02/15
SPL Interim Report and Half-Year Financial ResultsPRICE SENSITIVE16/02/15
SPL Appendix 3B30/01/15
SPL Appendix 4C - Quarterly Cashflow ReportPRICE SENSITIVE28/01/15
SPL Appendix 3B22/01/15
SPL Starpharma to present at Biotech Showcase12/01/15
SPL Appendix 3B23/12/14
SPL Change in Director's Interest Notice - R Thomas18/12/14
SPL Change in substantial holding17/12/14
SPL Change in Director's Interest Notice - J Fairley17/12/14
SPL Change in Director's Interest Notice - R Thomas08/12/14
SPL Japan VivaGel condom classification impacts launch timingPRICE SENSITIVE05/12/14
SPL Change in Director's Interest Notice - J Fairley03/12/14
SPL Appendix 3B03/12/14
SPL +Marketing Clearance for VivaGel condom in New ZealandPRICE SENSITIVE28/11/14
SPL Change of Company Address27/11/14
SPL Starpharma Adopts New Constitution20/11/14
SPL AGM Results20/11/14
SPL AGM - Chair Address and CEO's Presentation20/11/14
SPL Response to ASX Price QueryPRICE SENSITIVE17/11/14
SPL Starpharmas Priostar Glyphosate Patent Allowed in ChinaPRICE SENSITIVE13/11/14
SPL Change in Director's Interest Notice - R Hazleton06/11/14
SPL Change in Director's Interest Notice - P Turvey06/11/14
SPL Change in Director's Interest Notice - Z Peach06/11/14
SPL Change in Director's Interest Notice - P Jenkins06/11/14
SPL Change in Director's Interest Notice - R Thomas06/11/14
SPL Change of Director's Interest Notice - J Fairley06/11/14
SPL Appendix 3B - SPP05/11/14
SPL Appendix 4C - quarterlyPRICE SENSITIVE31/10/14
SPL Starpharma raises $3.5M through SPP following $18M Placement30/10/14
SPL Starpharma receives $4.2M R&D tax incentive refundPRICE SENSITIVE29/10/14
SPL +VivaGel condom now available in Australian stores29/10/14
SPL Share Purchase Plan28/10/14
SPL Starpharma Boardroom Radio Interview21/10/14
SPL Extension of Share Purchase Plan20/10/14
SPL DEP docetaxel - longer duration and increased exposurePRICE SENSITIVE20/10/14
SPL Notice of Annual General Meeting/Proxy Form16/10/14
SPL Change of Director's Interest Notice14/10/14
SPL Appendix 3B14/10/14
SPL Starpharma to present at US Drug Delivery Conference14/10/14
SPL Shareholder Update October 201407/10/14
SPL Change in substantial holding03/10/14
SPL +VivaGel condom approved for sale with launch imminentPRICE SENSITIVE02/10/14
SPL Date of Annual General Meeting01/10/14
SPL Change in substantial holding - correction01/10/14
SPL Change in substantial holding30/09/14
SPL Cleansing Statement29/09/14
SPL Appendix 3B - Share Placement29/09/14
SPL Share Purchase Plan offer documents26/09/14
SPL Appendix 3B25/09/14
SPL SPP Record Date ClarificationPRICE SENSITIVE22/09/14
SPL Starpharma completes A$18 million placement, SPP to followPRICE SENSITIVE22/09/14
SPL Trading HaltPRICE SENSITIVE18/09/14
SPL Annual report and full year financial resultsPRICE SENSITIVE13/08/14
SPL Appendix 4C - Quarterly Cashflow ReportPRICE SENSITIVE31/07/14
SPL VivaGel condom receives TGA device certificationPRICE SENSITIVE21/07/14
SPL FDA Grants SPA Agreement for Phase 3 Recurrent BV TrialPRICE SENSITIVE14/07/14
SPL Change of Director's Interest Notice01/07/14
SPL Change of Director's Interest Notice24/06/14
SPL Appendix 3B18/06/14
SPL Final Director's Interest Notice18/06/14
SPL Correction to Shareholder Update June 201413/06/14
SPL Rob Thomas succeeds retiring Chairman Peter Bartels13/06/14
SPL Shareholder Update June 201412/06/14
SPL Ceasing to be a substantial holder10/06/14
SPLBecoming a substantial holder06/06/14
SPLStarpharma clinical trial programs acceleratingPRICE SENSITIVE05/06/14
SPLChange in substantial holding30/05/14
SPLAppendix 3B22/05/14
SPLChange in substantial holding16/05/14
SPLAppendix 4C - Quarterly Cashflow ReportPRICE SENSITIVE30/04/14
SPLStarpharma expands Drug Delivery Program with AstraZenecaPRICE SENSITIVE07/04/14
SPLVivaGel-coated condom approved for marketing in JapanPRICE SENSITIVE14/03/14
SPLStarpharma receives $4.7M R&D tax incentive11/03/14
SPLStarpharma to present to US institutional investors27/02/14
SPLStarpharma Interim Report and Half-year Financial ResultsPRICE SENSITIVE24/02/14
SPLAppendix 3B19/02/14
SPLAppendix 3B30/01/14
SPLAppendix 4C - Quarterly Cashflow ReportPRICE SENSITIVE30/01/14
SPLChange in substantial holding28/01/14
SPLResponse to ASX Price QueryPRICE SENSITIVE23/01/14
SPLStarpharma commences Dendrimer-Docetaxel clinical trialPRICE SENSITIVE23/01/14
SPLChange in substantial holding14/01/14
SPLStarpharma to recoup additional $2 million for overseas R&DPRICE SENSITIVE14/01/14
SPLCancer Australia funding for dendrimer-based lung treatmentPRICE SENSITIVE19/12/13
SPLShareholder Update December 201317/12/13
SPLRetirement of Company Secretary10/12/13
SPLAppendix 3B06/12/13
SPLChange of Director's Interest Notice06/12/13
SPLAppendix 3B06/12/13
SPLInitial Director's Interest Notice05/12/13
SPLAppointment of Director05/12/13
SPLAppendix 3B02/12/13
SPLResults of Meeting22/11/13
SPL Appendix 4C - Quarterly Cashflow Report
30/04/15PRICE SENSITIVE
SPL DEP Docetaxel Trial Dose Exceeds Common Taxotere Dose Level
30/04/15PRICE SENSITIVE
SPL Securities Dealing Policy
22/04/15
SPL Shareholder Update March 2015
23/03/15
SPLShareholder Update March 2015
23/03/15
SPL Starpharma to present at March US investor conferences
05/03/15
SPL Starpharma presents at ASX Investor Series
17/02/15
SPL Interim Report and Half-Year Financial Results
16/02/15PRICE SENSITIVE
SPL Appendix 3B
30/01/15
SPL Appendix 4C - Quarterly Cashflow Report
28/01/15PRICE SENSITIVE
SPL Appendix 3B
22/01/15
SPL Starpharma to present at Biotech Showcase
12/01/15
SPL Appendix 3B
23/12/14
SPL Change in Director's Interest Notice - R Thomas
18/12/14
SPL Change in substantial holding
17/12/14
SPL Change in Director's Interest Notice - J Fairley
17/12/14
SPL Change in Director's Interest Notice - R Thomas
08/12/14
SPL Japan VivaGel condom classification impacts launch timing
05/12/14PRICE SENSITIVE
SPL Change in Director's Interest Notice - J Fairley
03/12/14
SPL Appendix 3B
03/12/14
SPL +Marketing Clearance for VivaGel condom in New Zealand
28/11/14PRICE SENSITIVE
SPL Change of Company Address
27/11/14
SPL Starpharma Adopts New Constitution
20/11/14
SPL AGM Results
20/11/14
SPL AGM - Chair Address and CEO's Presentation
20/11/14
SPL Response to ASX Price Query
17/11/14PRICE SENSITIVE
SPL Starpharmas Priostar Glyphosate Patent Allowed in China
13/11/14PRICE SENSITIVE
SPL Change in Director's Interest Notice - R Hazleton
06/11/14
SPL Change in Director's Interest Notice - P Turvey
06/11/14
SPL Change in Director's Interest Notice - Z Peach
06/11/14
SPL Change in Director's Interest Notice - P Jenkins
06/11/14
SPL Change in Director's Interest Notice - R Thomas
06/11/14
SPL Change of Director's Interest Notice - J Fairley
06/11/14
SPL Appendix 3B - SPP
05/11/14
SPL Appendix 4C - quarterly
31/10/14PRICE SENSITIVE
SPL Starpharma raises $3.5M through SPP following $18M Placement
30/10/14
SPL Starpharma receives $4.2M R&D tax incentive refund
29/10/14PRICE SENSITIVE
SPL +VivaGel condom now available in Australian stores
29/10/14
SPL Share Purchase Plan
28/10/14
SPL Starpharma Boardroom Radio Interview
21/10/14
SPL Extension of Share Purchase Plan
20/10/14
SPL DEP docetaxel - longer duration and increased exposure
20/10/14PRICE SENSITIVE
SPL Notice of Annual General Meeting/Proxy Form
16/10/14
SPL Change of Director's Interest Notice
14/10/14
SPL Appendix 3B
14/10/14
SPL Starpharma to present at US Drug Delivery Conference
14/10/14
SPL Shareholder Update October 2014
07/10/14
SPL Change in substantial holding
03/10/14
SPL +VivaGel condom approved for sale with launch imminent
02/10/14PRICE SENSITIVE
SPL Date of Annual General Meeting
01/10/14
SPL Change in substantial holding - correction
01/10/14
SPL Change in substantial holding
30/09/14
SPL Cleansing Statement
29/09/14
SPL Appendix 3B - Share Placement
29/09/14
SPL Share Purchase Plan offer documents
26/09/14
SPL Appendix 3B
25/09/14
SPL SPP Record Date Clarification
22/09/14PRICE SENSITIVE
SPL Starpharma completes A$18 million placement, SPP to follow
22/09/14PRICE SENSITIVE
SPL Trading Halt
18/09/14PRICE SENSITIVE
SPL Annual report and full year financial results
13/08/14PRICE SENSITIVE
SPL Appendix 4C - Quarterly Cashflow Report
31/07/14PRICE SENSITIVE
SPL VivaGel condom receives TGA device certification
21/07/14PRICE SENSITIVE
SPL FDA Grants SPA Agreement for Phase 3 Recurrent BV Trial
14/07/14PRICE SENSITIVE
SPL Change of Director's Interest Notice
01/07/14
SPL Change of Director's Interest Notice
24/06/14
SPL Appendix 3B
18/06/14
SPL Final Director's Interest Notice
18/06/14
SPL Correction to Shareholder Update June 2014
13/06/14
SPL Rob Thomas succeeds retiring Chairman Peter Bartels
13/06/14
SPL Shareholder Update June 2014
12/06/14
SPL Ceasing to be a substantial holder
10/06/14
SPLBecoming a substantial holder
06/06/14
SPLStarpharma clinical trial programs accelerating
05/06/14PRICE SENSITIVE
SPLChange in substantial holding
30/05/14
SPLAppendix 3B
22/05/14
SPLChange in substantial holding
16/05/14
SPLAppendix 4C - Quarterly Cashflow Report
30/04/14PRICE SENSITIVE
SPLStarpharma expands Drug Delivery Program with AstraZeneca
07/04/14PRICE SENSITIVE
SPLVivaGel-coated condom approved for marketing in Japan
14/03/14PRICE SENSITIVE
SPLStarpharma receives $4.7M R&D tax incentive
11/03/14
SPLStarpharma to present to US institutional investors
27/02/14
SPLStarpharma Interim Report and Half-year Financial Results
24/02/14PRICE SENSITIVE
SPLAppendix 3B
19/02/14
SPLAppendix 3B
30/01/14
SPLAppendix 4C - Quarterly Cashflow Report
30/01/14PRICE SENSITIVE
SPLChange in substantial holding
28/01/14
SPLResponse to ASX Price Query
23/01/14PRICE SENSITIVE
SPLStarpharma commences Dendrimer-Docetaxel clinical trial
23/01/14PRICE SENSITIVE
SPLChange in substantial holding
14/01/14
SPLStarpharma to recoup additional $2 million for overseas R&D
14/01/14PRICE SENSITIVE
SPLCancer Australia funding for dendrimer-based lung treatment
19/12/13PRICE SENSITIVE
SPLShareholder Update December 2013
17/12/13
SPLRetirement of Company Secretary
10/12/13
SPLAppendix 3B
06/12/13
SPLChange of Director's Interest Notice
06/12/13
SPLAppendix 3B
06/12/13
SPLInitial Director's Interest Notice
05/12/13
SPLAppointment of Director
05/12/13
SPLAppendix 3B
02/12/13
SPLResults of Meeting
22/11/13
refresh Created with Sketch. REFRESH
 
(20min delay)
Last
10.5¢ 		Change
0.000(0.00%) 		Mkt cap ! $43.82M
Open High Low Value Volume
10.5¢ 11.5¢ 10.0¢ $110.6K 1.006M

Buyers (Bids)

No. Vol. Price($)
1 83046 10.5¢
 

Sellers (Offers)

Price($) Vol. No.
11.0¢ 30000 1
View Market Depth
Last trade - 16.10pm 15/11/2024 (20 minute delay) ?
Last
10.5¢ 		  Change
0.000 ( 5.00 %)
Open High Low Volume
10.3¢ 11.5¢ 10.3¢ 347942
Last updated 15.58pm 15/11/2024 ?
SPL (ASX) Chart

Top Stories

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

Put simply: if 3D Printing is a gold rush, Amaero is selling shovels. Or maybe it's more like sneakers in an arms race.
Blue Star Helium sees approval for five more wells at 'Galactica/Pegasus' project in Colorado Blue Star Helium (ASX:BNL) has won approval from Colorado regulators to drill five fresh helium wells at its flagship.
NT Gov't delivers environmental approval for Empire Energy's Beetaloo Carpentaria pilot gas play Empire Energy (ASX:EEG) has confirmed the NT government has delivered environmental approvals for Carpentaria.
Week 46 Wrap: Copper hits 2mth low as Trump threatens net zero pace; US rally fades; HotCopper’s picks Copper prices slump; Trump Wall Street rally fades; US health stocks dip on RFK appointment – and much more.
InhaleRX gains approval for clinical trial to test non-opioid therapy for cancer pain InhaleRX Ltd has received approval for a Phase 2 clinical trial to test its novel therapy IRX-211 for treatment of Breakthrough Cancer Pain
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.